WCI

U.S. Worker Confidence Index™ Reached Highest Level Ever in Q4 2023

Retrieved on: 
Tuesday, March 5, 2024
Acquisition, African Americans, Woman, HRO, News, Work (human activity), African, Growth, Calendar, Human, History, WCI, Trust, Likelihood function, Day & Zimmermann, Ageing, Video game

PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- After nine months of decline, the U.S. Worker Confidence Index™ (WCI) not only saw an increase in Q4 2023 but reached its highest level ever in the nearly 10-year history of the survey.

Key Points: 
  • PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- After nine months of decline, the U.S. Worker Confidence Index™ (WCI) not only saw an increase in Q4 2023 but reached its highest level ever in the nearly 10-year history of the survey.
  • A more positive perspective shows that the Index is still 10.9 points higher in Q4 2023 than it was in Q4 2022.
  • Workers aged 25–34 held the highest level of confidence, with nearly half (43.5%) anticipating a promotion.
  • Workers aged 35–44 had the highest level of trust, as 61.5% said they trusted their leadership.

Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, February 26, 2024
AAAAI, Injection, KIT, Research, Dermatology, Omalizumab, Eosinophilic esophagitis, B cell, Hypersensitivity, Quality of life, Work, Prurigo nodularis, Loss, DLQI, ILT4, Data, PD-1, Contingency, Inflammation, Cell, Myelocyte, Rockefeller University, Therapy, PN, Allergy, WCI, UAS7, Patient, Dermatology Life Quality Index, CSU, Survival, Congress, Disease, G&A, Itch, SRS, American Academy, Pharmaceutical industry

HAMPTON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • Celldex is currently planning two Phase 3 studies of barzolvolimab in CSU, which are expected to initiate this summer.
  • Celldex is currently planning for the initiation of a Phase 2 subcutaneous study in prurigo nodularis (PN) in early 2024.
  • The litigation settlement related loss had a ($0.26) impact on net loss per share for the twelve months ended December 31, 2023.
  • Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2023 are sufficient to meet estimated working capital requirements and fund current planned operations into 2026.

Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab

Retrieved on: 
Sunday, November 5, 2023
Survival, Patient, KIT, WCI, Social isolation, PN, Itch, Neuron, B cell, Skin, Conference, Sleep, Bleeding, Abstract (summary), CQD, Quality of life, Neuroinflammation, IGA, Prurigo nodularis, Disease, Hives, Depression, Safety, Anxiety, Mast cell, Therapy, Pain, Conference call, Vaccine, Pharmaceutical industry, Dermatology

HAMPTON, N.J., Nov. 05, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from the Company’s Phase 1b study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. Mast cells are believed to play an important role in amplifying chronic itch and neuroinflammation, including in PN. This study is the first to demonstrate that barzolvolimab, a mast cell depleting agent, can potentially be used to treat PN and other chronic itch indications. The data will be presented in an oral presentation during the “Hot Topics” Session at the 12th World Congress on Itch (WCI) 2023 on Tuesday, November 7th by Martin Metz, M.D., Professor of Dermatology and Allergy at Charité - Universitätsmedizin in Berlin. Abstracts accepted for presentation at the meeting were released today.

Key Points: 
  • - Conference call to be held on Monday, November 6th at 8:00 am ET to discuss study results -
    HAMPTON, N.J., Nov. 05, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from the Company’s Phase 1b study of barzolvolimab in prurigo nodularis (PN).
  • Mast cells are believed to play an important role in amplifying chronic itch and neuroinflammation, including in PN.
  • This study is the first to demonstrate that barzolvolimab, a mast cell depleting agent, can potentially be used to treat PN and other chronic itch indications.
  • The Phase 1b double-blind, single intravenous (IV) dose study randomized 24 adults (evaluable: n=23 safety; n=22 efficacy) with moderate to severe PN across three arms: (1) barzolvolimab 3.0 mg/kg (n=9), barzolvolimab 1.5 mg/kg (n=7) and placebo (n=8).

Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 2, 2023
CSU, DLQI, Prurigo, Science, Survival, WCI, KIT, Research, Dermatology Life Quality Index, PN, Contingency, Congress, G&A, Work, B cell, PD-1, Cell, R, Quality of life, European Academy of Management, SD, Prurigo nodularis, Myelocyte, Disease, UCT, Eosinophilic esophagitis, Allergy, Georgia World Congress Center, ILT4, Therapy, Patient, Rockefeller University, SCF, Hypersensitivity, D, Pharmaceutical industry, Vaccine, Rare-earth element, Cryptocurrency, Dermatology

HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • - Phase 2 CSU enrollment complete; topline data by YE 2023 -
    HAMPTON, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.
  • In July 2023, Celldex announced that enrollment to the CSU study (n=208) had been completed and that topline data is anticipated by the end of 2023.
  • Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2023 were $235.3 million compared to $252.7 million as of June 30, 2023.

Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023

Retrieved on: 
Tuesday, September 26, 2023
Prurigo nodularis, Therapy, Patient, Skin, WCI, Pharmaceutical industry

HAMPTON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodularis (PN) has been accepted as an oral presentation at the 12th World Congress on Itch (WCI), being held in Miami on Nov 5-7, 2023.

Key Points: 
  • HAMPTON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodularis (PN) has been accepted as an oral presentation at the 12th World Congress on Itch (WCI), being held in Miami on Nov 5-7, 2023.
  • The Phase 1b multi-center, randomized, double-blind, placebo-controlled trial is designed to study barzolvolimab in patients with prurigo nodularis (PN), a chronic skin disease characterized by the development of hard, intensely itchy (pruritic) nodules on the skin.

Visa Releases First Growth Corporates Working Capital Index for the Middle-Market

Retrieved on: 
Wednesday, September 13, 2023
Finance, Business, Payments, Professional Services, Technology, Treasury, DPO, Multimedia, WCI, CFOS, Organization, Growth, System, Health, SVP, NYSE, Renewable energy, Airline, Management, Online shopping, Visa

View the full release here: https://www.businesswire.com/news/home/20230913696739/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230913696739/en/
    Visa Releases First Growth Corporates Working Capital Index for the Middle-Market (Graphic: Business Wire)
    The findings revealed these organizations face challenges securing working capital solutions that fit the unique operational and financial needs of their business.
  • Nearly half of surveyed growth corporates plan to use more working capital in the year ahead for strategic growth initiatives, yet 18% currently sub-optimize use of working capital, either due to a lack of access or a misalignment of the working capital solutions to their sector-specific requirements.
  • The Working Capital Index highlights that nearly a third (32%) of surveyed growth corporates used external working capital solutions for strategic growth purposes to fund business expansion, buy inventory, upgrade legacy systems, and other growth initiatives.
  • “Visa is pleased to introduce the 2023-2024 Growth Corporates Working Capital Index, which takes a closer look at the middle-market business community and how they are approaching working capital challenges,” stated Darren Parslow, global head, Visa Commercial Solutions.

U.S. Worker Confidence Index™ Falls for 2nd Consecutive Quarter, Led by Another Sharp Decline in Perceived Likelihood of Raise

Retrieved on: 
Wednesday, August 23, 2023
Workforce, Education, Confidence, Fear, Woman, Job satisfaction, WCI, Day & Zimmermann, Organization, HRO, Ageing, African Americans, Video game, Nursing

In the second quarter of 2023, the WCI fell by 2.2 points from 110.9 to 108.7, the second consecutive quarter of decreases.

Key Points: 
  • In the second quarter of 2023, the WCI fell by 2.2 points from 110.9 to 108.7, the second consecutive quarter of decreases.
  • Of the four indices comprising the WCI, only perceived job security increased, jumping 6.3 points from 95.9 to 102.2.
  • Meanwhile, anticipation of a raise saw the sharpest decline, falling by 7 points from 115.9 to 108.9, its lowest level in a year.
  • Overall, less than one-third (29.8%) of workers said they anticipated a raise of at least 3% after their next performance review.

MEMIC Selects Gradient AI to Gain Competitive Advantage in Its Workers’ Compensation Claims Operations

Retrieved on: 
Monday, August 21, 2023
Software, Insurance, Networks, Data Analytics, Artificial Intelligence, Data Management, Professional Services, Technology, Pressure, Benchmarking, Intelligence, Adequate Public Facilities Ordinance, WCI, Gradient, Machine learning, Artificial intelligence, Comp, SVP, Conference, Safety, Risk management, Uranium mining

Having already harnessed Gradient AI’s underwriting solution to enhance risk prediction and capture institutional knowledge, MEMIC has now chosen Gradient AI to enhance its claims management outcomes.

Key Points: 
  • Having already harnessed Gradient AI’s underwriting solution to enhance risk prediction and capture institutional knowledge, MEMIC has now chosen Gradient AI to enhance its claims management outcomes.
  • Under this expanded agreement, MEMIC will leverage the advanced capabilities of Gradient AI’s Claims Benchmarking and Total Incurred Prediction solutions.
  • With approximately 11,000 open claims at any given time, MEMIC is constantly looking for strategies to improve the efficiency and accuracy of its claims management operations.
  • “Our claim team is excellent but Gradient AI takes our game to a new level,” said Matt Harmon, SVP of Claims at MEMIC.

Major Upgrades to the ISA100 Wireless(TM) Product Capabilities

Retrieved on: 
Thursday, August 17, 2023
ODVA, Bluetooth Low Energy, OPC, Wireless Compliance Institute, BLE, NAMUR, Process, Joint Working Group between the Roman Catholic Church and the World Council of Churches, PNO, OPC Foundation, WCI, ANSI, International Society of Automation, FCG, Wireless, ISA, Radio, IEC, Joint, VDMA, International Society, Mobile phone

ISA100 Wireless now supports Bluetooth Low Energy and OPC-UA

Key Points: 
  • As a complementary technology, BLE will enable provisioning and commissioning of ISA100 Wireless field devices by Bluetooth-enabled handhelds, especially by ubiquitous mobile phones.
  • These new capabilities bring ISA100 Wireless technology to current state-of-art and improve user's experience when new devices are configured and deployed.
  • Together, these ISA100 Wireless enhancements will improve interoperability and the overall user experience in the ISA100 Wireless community.
  • WCI members will describe these new ISA100 Wireless capabilities during a webinar scheduled for 30 August 2023.

NRU Reactor Recognized for Outstanding Contributions in the Field of Isotopes

Retrieved on: 
Friday, July 28, 2023
Canadian Nuclear Laboratories Research Facilities, CNL, NRU, AECL, National Research Universal reactor, CANDU, Cancer, Woman, Ottawa Valley, Research, Reactor, History, WCI, Atomic Energy of Canada Limited, Science, Nuclear medicine, Chemistry, Tehran International Conference on Disarmament and Non-Proliferation, ARD International Music Competition, Engineering, Diagnosis, Conference, Carbon-14, Uranium mining, Medical imaging, Isotope

SASKATOON, Saskatchewan, July 28, 2023 (GLOBE NEWSWIRE) -- Atomic Energy of Canada Limited (AECL), Canada’s nuclear Crown corporation, and Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology laboratory, are pleased to announce that the National Research Universal (NRU) Reactor has received the 2023 World Council of Isotopes (WCI) President’s Award for over 60 years of service in the research, production and delivery of isotopes. CNL accepted the award on behalf of AECL, who owns and operated the facility during its service lifetime, and on behalf of the thousands of talented and dedicated men and women who designed, built and operated the NRU, at the 11th International Conference on Isotopes (11ICI) yesterday in Saskatoon, SK.

Key Points: 
  • A landmark achievement in Canadian nuclear science and technology, the NRU reactor would go on to produce isotopes that were used in over 1 billion medical procedures, impacting the lives of people all over the world.
  • “We are proud to receive this recognition, and even more proud of Canada’s nuclear heritage and the contributions that the NRU made to global nuclear science.
  • The medical isotopes created by the NRU benefited millions of people every year, in more than 80 countries.
  • If you would like to learn more about the NRU reactor and its history in Canadian nuclear science and technology, you can access the documentary on CNL’s YouTube page at www.cnl.ca/nru-movie .